Company intelligence / Profile preview

DOF

Ownership: Private
Development stage: Other

Overview

DOF is an institution approved by the Ministry of Food and Drug Safety in South Korea to collect, store, process, and distribute donated human tissues for use in regenerative medicine. It operates a comprehensive platform supporting hospitals and clinics with high-quality tissue products for transplantation procedures.

Therapeutic areas: Immunology
Modalities: Tissue-based therapy
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on DOF.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DOF.